You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALKS 4230

Showing 1 - 25 of 48
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-cutaneous Squamous Cell Carcinoma of Head and Neck Trial in United States (ALKS 4230, Pembrolizumab)

Completed
  • Non-cutaneous Squamous Cell Carcinoma of Head and Neck
  • Miami, Florida
  • +5 more
Nov 10, 2022

Advanced Solid Tumors Trial in Worldwide (ALKS 4230, ALKS 4230 + pembrolizumab)

Active, not recruiting
  • Advanced Solid Tumors
  • ALKS 4230
  • ALKS 4230 + pembrolizumab
  • Denver, Colorado
  • +30 more
Nov 23, 2022

Advanced Solid Tumor Trial in United States (Nemvaleukin alfa, Pembrolizumab)

Recruiting
  • Advanced Solid Tumor
  • Nemvaleukin alfa
  • Pembrolizumab
  • Grand Rapids, Michigan
  • +3 more
Aug 30, 2022

Cutaneous Melanoma, Mucosal Melanoma Trial in Worldwide (Nemvaleukin Alfa Subcutaneous, Nemvaleukin Alfa Intravenous)

Recruiting
  • Cutaneous Melanoma
  • Mucosal Melanoma
  • Nemvaleukin Alfa Subcutaneous
  • Nemvaleukin Alfa Intravenous
  • La Jolla, California
  • +26 more
Aug 1, 2022

Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Canada, United States (Nemvaleukin

Recruiting
  • Platinum-resistant Ovarian Cancer
  • +2 more
  • Nemvaleukin and Pembrolizumab Combination
  • +6 more
  • Ventura, California
  • +7 more
Aug 5, 2022

Advanced Solid Tumors Trial in Worldwide (ALKS 4230, Pembrolizumab)

Recruiting
  • Advanced Solid Tumors
  • ALKS 4230
  • Pembrolizumab
  • Los Angeles, California
  • +48 more
Feb 1, 2022

CNS Diseases Trial in Brisbane (Placebo, ALKS 1140)

Suspended
  • Central Nervous System Diseases
  • Placebo
  • ALKS 1140
  • Brisbane, Australia
    Alkermes Clinical Investigative Site
Feb 16, 2022

Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder Trial in Worldwide (ALKS 3831)

Active, not recruiting
  • Schizophrenia
  • +2 more
  • ALKS 3831
  • Little Rock, Arkansas
  • +85 more
Feb 10, 2022

Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder Trial in Worldwide (ALKS 3831, Olanzapine)

Completed
  • Schizophrenia
  • +2 more
  • Little Rock, Arkansas
  • +56 more
Jan 5, 2022

Schizophrenia, Alcohol Use Disorder Trial in Bulgaria, Poland, United States (Samidorphan + olanzapine (ALKS 3831), Placebo +

Completed
Has Results
  • Schizophrenia
  • Alcohol Use Disorder
  • Samidorphan + olanzapine (ALKS 3831)
  • Placebo + olanzapine
  • Little Rock, Arkansas
  • +70 more
Sep 14, 2021

Refractory MDD Trial in Australia, Puerto Rico, United States (ALKS 5461)

Terminated
Has Results
  • Refractory Major Depressive Disorder
  • ALKS 5461
  • Tucson, Arizona
  • +33 more
Jun 29, 2021

Schizophrenia Trial in Puerto Rico, United States (ALKS 3831)

Completed
Has Results
  • Schizophrenia
  • ALKS 3831
  • Little Rock, Arkansas
  • +44 more
Jul 20, 2021

MDD Trial in Australia, Puerto Rico, United States (ALKS 5461, ALKS 5461 Placebo)

Completed
Has Results
  • Major Depressive Disorder
  • ALKS 5461
  • ALKS 5461 Placebo
  • Tucson, Arizona
  • +34 more
Mar 15, 2021

Schizophrenia Trial in Bulgaria, Czechia, United States (Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High

Completed
Has Results
  • Schizophrenia
  • Samidorphan (Low Dose)
  • +4 more
  • Little Rock, Arkansas
  • +60 more
Sep 10, 2021

Relapsing Remitting Multiple Sclerosis Trial in Germany, Poland, United States (ALKS 8700, Dimethyl Fumarate)

Completed
Has Results
  • Relapsing Remitting Multiple Sclerosis
  • ALKS 8700
  • Dimethyl Fumarate
  • Cullman, Alabama
  • +66 more
Jul 13, 2020

Coeliac Disease in Spain: Determination of Disease Prevalence

Recruiting
  • Celiac Disease
    • Terrassa, Barcelona, Spain
      Hospital Universitari Mutua Terrassa
    Nov 3, 2021

    Schizophrenia Trial in Puerto Rico, United States (ALKS 3831, Olanzapine)

    Completed
    Has Results
    • Schizophrenia
    • Little Rock, Arkansas
    • +53 more
    Jan 29, 2020

    Multiple Sclerosis Trial in Austin (Study Drug, Active Control, Placebo)

    Completed
    • Multiple Sclerosis
    • Study Drug
    • +2 more
    • Austin, Texas
      Alkermes Investigational Site
    Nov 22, 2019

    MDD Trial in Australia, Canada, United States (High Dose ALKS 5461, Low Dose ALKS 5461, Placebo)

    Completed
    Has Results
    • Major Depressive Disorder
    • High Dose ALKS 5461
    • +2 more
    • Birmingham, Alabama
    • +48 more
    Aug 2, 2019

    MDD Trial in Worldwide (ALKS 5461, Placebo)

    Completed
    Has Results
    • Major Depressive Disorder
    • ALKS 5461
    • Placebo
    • Birmingham, Alabama
    • +43 more
    Aug 2, 2019

    MDD Trial in Canada, United States (ALKS 5461)

    Completed
    Has Results
    • Major Depressive Disorder
    • ALKS 5461
    • Jacksonville, Florida
    • +8 more
    Aug 2, 2019

    Schizophrenia Trial in Worldwide (ALKS 3831)

    Completed
    Has Results
    • Schizophrenia
    • ALKS 3831
    • Little Rock, Arkansas
    • +30 more
    Jul 15, 2019

    MDD Trial in Bulgaria, United States (ALKS 5461, Placebo)

    Completed
    Has Results
    • Major Depressive Disorder
    • ALKS 5461
    • Placebo
    • Little Rock, Arkansas
    • +57 more
    May 31, 2019

    MDD Trial in United States (ALKS 5461, Placebo)

    Completed
    Has Results
    • Major Depressive Disorder
    • ALKS 5461
    • Placebo
    • Tucson, Arizona
    • +26 more
    Apr 26, 2019

    Schizophrenia Trial in Worldwide (ALKS 9072, Placebo)

    Completed
    Has Results
    • Schizophrenia
    • ALKS 9072
    • Placebo
    • Little Rock, Arkansas
    • +83 more
    Jan 14, 2019